Use of compound or composition comprising NLRP1 inflammasome activation inhibitor for treatment of human airway inflammation

• Main Authors: ZHONG LEI, ROBINSON, KEVIN, S, REVERSADE BRUNO
• Format: Patent
• Language: Chinese; English
• Published: 30.12.2022
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present invention relates to a method of preventing or treating airway inflammation and/or related complications triggered by enterovirus 3C protease activated NLRP1 by using a compound or composition comprising an inhibitor of NLRP1 inflammasome activation. In one embodiment, the enterovirus 3C protease is from a viral species selected from the group consisting of human enterovirus A (HEV-A), human enterovirus B (HEV-B), human enterovirus C (HEV-C), human enterovirus D (HEV-D), human rhinovirus A (HRV-A), human rhinovirus B (HRV-B), and human rhinovirus C (HRV-C). In some embodiments, the compound is selected from the group consisting of MLN 4924, TAS4464, ZM223, MG132, and bortezomib. 本发明涉及一种通过使用包含NLRP1炎性体激活抑制剂的化合物或组合物来预防或治疗由肠道病毒3C蛋白酶激活的NLRP1触发的气道炎症和/或相关并发症的方法。在一个实施方案中，所述肠道病毒3C蛋白酶来自选自以下的病毒物种：人肠道病毒A(HEV-A)、人肠道病毒B(HEV-B)、人肠道病毒C(HEV-C)、人肠道病毒D(HEV-D)、人鼻病毒A(HRV-A)、人鼻病毒B(HRV-B)和人鼻病毒C(HRV-C)。在一些实施方案中，所述化合物选自MLN4924、TAS4464、ZM223、MG132和硼替佐米。